NanoViricides Secures $6 Million in Financing to Advance Antiviral Drug Development

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral nanomedicines, has entered into a securities purchase agreement with a single healthcare institutional investor for the purchase of 3,571,429 shares of common stock at $1.68 per share in a registered direct offering. The transaction is expected to generate approximately $6 million in gross proceeds before expenses, providing crucial capital for the company's antiviral drug development programs.

In a concurrent private placement, the company will issue Series A warrants and Series B warrants to purchase up to 3,571,429 shares each. The Series A warrants carry an exercise price of $1.75 per share and will be exercisable six months after issuance, expiring in two years. The Series B warrants have an exercise price of $2.00 per share, becoming exercisable after six months and expiring in 5.5 years. The closing of the offering is expected on or about November 12, 2025, subject to customary closing conditions, with A.G.P./Alliance Global Partners acting as sole placement agent for the transaction.

The proceeds from this financing will be used for working capital and general corporate purposes, supporting the company's ongoing research and development efforts. This funding comes at a critical time as NanoViricides advances its lead drug candidate, NV-387, toward Phase II human clinical trials. NV-387 represents a broad-spectrum antiviral drug that the company plans to develop as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections.

NanoViricides' platform technology and programs are based on the TheraCour nanomedicine technology licensed from TheraCour Pharma, Inc. The company holds a worldwide exclusive perpetual license to this technology for several drugs targeting specific viral diseases, including Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B and C viruses, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. Additional information about the company's technology and development programs can be found at https://www.nanoviricides.com.

The company's other advanced drug candidate, NV-HHV-1, is being developed for the treatment of Shingles, while additional pipeline programs target oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The company intends to obtain licenses for RSV, Poxviruses, and/or Enteroviruses if initial research proves successful.

This financing represents a significant step forward for NanoViricides as it continues to develop its novel nanoviricide class of drug candidates. The company's business model, established at its foundation in 2005, involves licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses. The successful completion of this $6 million offering provides the necessary capital to advance these promising antiviral therapies through critical development stages, potentially addressing significant unmet medical needs in viral disease treatment.

The development of broad-spectrum antiviral therapies has gained increased importance following global viral outbreaks, and NanoViricides' platform technology offers a unique approach to addressing multiple viral threats. However, as with any pharmaceutical development program, the path to successful drug approval remains lengthy and requires substantial capital investment, with no guarantee that any candidate will demonstrate sufficient effectiveness and safety for human clinical development. The company's progress can be monitored through regulatory filings and announcements available at https://ibn.fm/NNVC.